Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Jun 25;58(12):1826-33.
doi: 10.1212/wnl.58.12.1826.

Prevalence of narcolepsy symptomatology and diagnosis in the European general population

Affiliations

Prevalence of narcolepsy symptomatology and diagnosis in the European general population

M M Ohayon et al. Neurology. .

Abstract

Objective: To determine the prevalence of narcolepsy in the general population of five European countries (target population 205,890,882 inhabitants).

Methods: Overall, 18,980 randomly selected subjects were interviewed (participation rate 80.4%). These subjects were representative of the general population of the UK, Germany, Italy, Portugal, and Spain. They were interviewed by telephone using the Sleep-EVAL expert system, which provided narcolepsy diagnosis according to the International Classification of Sleep Disorders (ICSD).

Results: Excessive daytime sleepiness was reported by 15% of the sample, with a higher prevalence in the UK and Germany. Napping two times or more in the same day was reported by 1.6% of the sample, with a significantly higher rate in Germany. Cataplexy (episodes of loss of muscle function related to a strong emotion), a cardinal symptom of narcolepsy, was found in 1.6% of the sample. An ICSD narcolepsy diagnosis was found in 0.047% of the sample: The narcolepsy was severe for 0.026% of the sample and moderate in 0.021%.

Conclusion: This is the first epidemiologic study that estimates the prevalence of narcolepsy in the general population of these five European countries. The disorder affects 47 individuals/100,000 inhabitants.

PubMed Disclaimer

Similar articles

Cited by

  • Methylphenidate and atomoxetine prescribing trends in children in the Western Cape Province of South Africa, 2005-2013.
    Joubert L, Burger JR, Truter I, Lubbe MS, Cockeran M. Joubert L, et al. Health SA. 2018 Jul 31;23:1084. doi: 10.4102/hsag.v23i0.1084. eCollection 2018. Health SA. 2018. PMID: 31934380 Free PMC article.
  • Immunotherapy in Narcolepsy.
    Giannoccaro MP, Sallemi G, Liguori R, Plazzi G, Pizza F. Giannoccaro MP, et al. Curr Treat Options Neurol. 2020 Jan 30;22(1):2. doi: 10.1007/s11940-020-0609-7. Curr Treat Options Neurol. 2020. PMID: 31997035 Review.
  • Migraine and sleep disorders: a systematic review.
    Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, Hubalek IA, Marchenko Y, Overeem LH, Piroso S, Tkachev A, Martelletti P, Sacco S; European Headache Federation School of Advanced Studies (EHF-SAS). Tiseo C, et al. J Headache Pain. 2020 Oct 27;21(1):126. doi: 10.1186/s10194-020-01192-5. J Headache Pain. 2020. PMID: 33109076 Free PMC article.
  • Narcolepsy Presentation in Diverse Populations: an Update.
    Spruyt K. Spruyt K. Curr Sleep Med Rep. 2020;6(4):239-250. doi: 10.1007/s40675-020-00195-7. Epub 2020 Nov 25. Curr Sleep Med Rep. 2020. PMID: 33251089 Free PMC article. Review.
  • Probability estimation of narcolepsy type 1 in DTA mice using unlabeled EEG and EMG data.
    Rose L, Zahid AN, Piilgaard L, Egebjerg C, Sørensen FL, Andersen M, Radovanovic T, Tsopanidou A, Bastianini S, Berteotti C, Lo Martire V, Borsa M, Tisdale RK, Sun Y, Nedergaard M, Silvani A, Zoccoli G, Adamantidis A, Kilduff TS, Sakai N, Nishino S, Arthaud S, Peyron C, Fort P, Mørup M, Mignot E, Kornum BR. Rose L, et al. Sleep Adv. 2025 May 10;6(2):zpaf025. doi: 10.1093/sleepadvances/zpaf025. eCollection 2025 Apr. Sleep Adv. 2025. PMID: 40521226 Free PMC article.

Publication types

LinkOut - more resources